Company intelligence / Profile preview
Psy Therapeutics
Boston, Massachusetts, United Statespsythx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Lead product PSY-05001 is in pre-clinical development for the treatment of Chronic Pain and Sleep Disturbance in PTSD. The company is expecting data on transgenic mouse studies for their PSY-02 (Tau) program in June 2025.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
X-Chem, Inc.IntelliSynReaction Biology CorporationSai Life SciencesPiramal
Beyond the preview
Go deeper on Psy Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Psy Therapeutics.